Physician profile
Stanley Eugene Koontz
NPI 1780662411
$747.01
in general payments reported to CMS, 2019-2025
22 companies · $71.78 in 2025
The $71.78 reported for 2025 was more than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $64.21 · 2021: $178 · 2022: $47.51 · 2023: $115 · 2024: $158 · 2025: $71.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $120.43 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $62.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.27 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $52.73 | 2020-2024 | Xarelto |
| Lilly USA, LLC | $50.91 | 2023-2024 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $49.02 | 2019-2021 | |
| Csl Behring | $43.45 | 2019-2021 | |
| Daiichi Sankyo INC. | $39.20 | 2020-2023 | Injectafer |
| Eisai INC. | $33.37 | 2020-2021 | |
| Abbvie INC. | $26.69 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $26.34 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.07 | 2025 | Xifaxan |
| Portola Pharmaceuticals, LLC | $24.13 | 2019 | |
| Antares Pharma, INC. | $19.54 | 2021 | |
| Allergan, INC. | $18.13 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $16.46 | 2025 | Inspire |
| Azurity Pharmaceuticals, INC. | $16.44 | 2025 | Alvesco |
| Idorsia Pharmaceuticals US INC | $13.84 | 2022 | |
| Pfizer INC. | $13.61 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.60 | 2021 | |
| Merck Sharp & Dohme LLC | $12.09 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Koontz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.